🇺🇸 FDA
Patent

US 10683504

Serpina1 iRNA compositions and methods of use thereof

granted A61KA61K31/712A61K31/713

Quick answer

US patent 10683504 (Serpina1 iRNA compositions and methods of use thereof) held by Alnylam Pharmaceuticals, Inc. expires Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Alnylam Pharmaceuticals, Inc.
Grant date
Tue Jun 16 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 11 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K31/712, A61K31/713, A61P, A61P1/00